Use of anti-(+)-methamphetamine monoclonal antibody to significantly alter (+)-methamphetamine and (+)-amphetamine disposition in rats

Drug Metabolism and Disposition

Volumn 31, Issue 11, 2003, Pages 1320-1326

  Laurenzana, Elizabeth M ^a   Byrnes Blake, Kelly A ^a,b   Milesi Hallé, Alessandra ^a   Gentry, W Brooks ^a   Williams, D Keith ^a   Owens, S Michael ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b ZYMOGENETICS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHETAMINE; BUFFER; DRUG METABOLITE; METHAMPHETAMINE; METHAMPHETAMINE MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 6H4; UNCLASSIFIED DRUG;

ANIMAL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY AFFINITY; AREA UNDER THE CURVE; ARTICLE; BRAIN PROTECTION; BRAIN TISSUE; COMPARATIVE STUDY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG BINDING SITE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CROSS REACTIVITY; DRUG DISPOSITION; DRUG EFFECT; DRUG METABOLISM; DRUG PROTEIN BINDING; IMMUNOLOGY; LIVER; MALE; NONHUMAN; PHYSIOLOGY; PLASMA PROTEIN BINDING; PRIORITY JOURNAL; RAT; RAT STRAIN; SERUM; TISSUE DISTRIBUTION;

AMPHETAMINE; ANIMALS; ANTIBODIES, MONOCLONAL; MALE; METHAMPHETAMINE; RATS; RATS, SPRAGUE-DAWLEY; TISSUE DISTRIBUTION;

ANIMALIA;

EID: 0142212156     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: 10.1124/dmd.31.11.1320     Document Type: Article

References (25)

1. Baxter LT, Zhu H, Mackensen DG, and Jain RK (1994) Physiology based pharmacokinetic model for specific and nonspecific monoclonal antibodies and fragments in normal tissues and human tumor xenografts in nude mice. Cancer Res 54:1517-1528.
2. Baxter LT, Zhu H, Mackensen DG, Butler WF, and Jain RK (1995) Biodistribution of monoclonal antibodies: scale-up form mouse to human using a physiology based pharmacokinetic model. Cancer Res 55:4611-4622.
3. Bazin-Redureau MI, Renard CB, and Scherrmann JM (1997) Pharmacokinetics of heterologous and homologous immunoglobulin G. F(ab′)2 and Fab after intravenous administration in the rat. J Pharm Pharmacol 49:277-281.
4. Byrnes-Blake KA, Laurenzana EM, Carroll FI, Abraham P, Gentry WB, Landes RD, and Owens SM (2003) Pharmacodynamic mechanisms of monoclonal antibody-based antagonism of (+)-methamphetamine in rats. Eur J Pharmacol 461:119-128.
5. Hardin JS, Wessinger WD, Proksch JW, and Owens SM (1998) Pharmacodynamics of a monoclonal antiphencyclidine Fab with broad selectivity for phencyclidine-like drugs. J Pharmacol Exp Ther 285:1113-1122.
6. Hardin JS, Wessinger WD, Wenger GR, Proksch JW, Laurenzana EM, and Owens SM (2002) A single dose of monoclonanl anti-phencyclidine IgG offers long-term reductions in phencyclidine behavioral effects in rats. J Pharmacol Exp Ther 302:119-126.
7. Hong G, Bazin-Rodureau MI, and Scherrmann JM (1999) Pharmacokinetics and organ distribution of cationized colchicine-specific IgG and Fab fragments in rat. J Pharm Sci 88:147-153.
8. Knapp MJ and Colburn PA (1990) Clinical uses of intravenous immune globulin. Clin Pharm 9:509-529.
9. Kosugi I, Muro H, Shirasawa H, and Ito I (1992) Endocytosis of soluble IgG immune comples and its transport to lysosomes in hepatic sinusoidal cells. Hepatology 16:106-114.
10. Kreek MJ, Laforge KS, and Butelman E (2002) Pharmacotherapy of addictions. Nat Rev Drug Discov 1:710-726.
11. Malin DH, Lake JR, Lin A, Saldaña M, Balch L, Irvin ML, Chandrasekara H, Alvarado CL, Hieda Y, Keyler DE, et al. (2001) Passive immunization against nicotine prevents nicotine alleviation of nicotine abstinence syndrome. Pharmacol Biochem Behav 68:87-92.
12. Mannik M and Arend WP (1971) Pate of preformed immune complexes in rabbits and rhesus monkeys. J Exp Med 134:19S-31S.
13. Nedelman JR, Gibiansky E, and Lau DTW (1995) Applying Bailer's method for AUC confidence interval to sparse sampling. Pharm Res (NY) 12:124-183.
14. Pentel PR, Keyler DE, Brunn GJ, Milavetz JM, Gilbertson DG, Matta SG, and Pond SM (1991) Redistribution of tricyclic antidepressants in rats using a drug-specific monoclonal antibody: dose response relationship. Drug Metabol Dispos 19:24-28.
15. Proksch JW, Gentry WB, and Owens SM (2000) Anti-phencyclidine monoclonal antibodies provide long-term reductions in brain phencyclidine concentrations during chronic phencyclidine administration in rats. J Pharmacol Exp Ther 292:831-837.
16. Ragusi C, Boschi G, Risède P, Rips R, Harrison K, and Scherrmann J-M (1998) Influence of various combinations of specific antibody dose and affinity on tissue imipramine redistribution. Br J Pharamacol 125:35-40.
17. Rivière GJ, Byrnes KA, Gentry WB, and Owens SM (1999) Spontaneous locomotor activity and pharmacokinetics of intravenous methamphetamine and its metabolite amphetamine in the rat. J Pharmacol Exp Ther 291:1220-1226.
18. Rivière GJ, Gentry WB, and Owens SM (2000) Disposition of methamphetamine and its metabolite amphetamine in brain and other tissues in rats after intravenous administration. J Pharmacol Exp Ther 292:1042-1047.
19. Schlachetzki F, Zhu C, and Pardridge WM (2002) Expression of the neonatal Fc receptor (FcRn) at the blood brain barrier. J Neurochemistry 81:203-206.
20. Skough T, Blomhoff R, Eskild W, and Berg T (1985) Hepatic uptake of circulating IgG immune compexes. Immunology 55:585-594.
21. Spiegelberg HL and Weigle WO (1967) The immune response to human gamma-G-immunoglobulin in rabbits unresponsive to Fc fragment and H chain protein. J Immunol 98:1020-1027.
22. Sullivan JB Jr (1986) Immunotherapy in the poisoned patient. Overview of present applications and future trends. Med Toxicol 1:47-60.
23. Valentine JL, Mayersohn M, Wessinger WD, Arnold LW, and Owens SM (1996) Antiphencyclidine monoclonal Fab fragments reverse phencyclidine-induced behavioral effects and ataxia in rats. J Pharmacol Exp Ther 278:709-716.
24. Valentine JL and Owens SM (1996) Antiphencyclidine monoclonal antibody therapy significantly changes phencyclidine concentrations in brain and other tissues in rats. J Pharmacol Exp Ther 278:717-724.
25. Zhang Y and Pardridge WM (2001) Mediated efflux of IgG molecules from the brain to blood across the blood-brain barrier. J Neuroimmunol 114:168-172.